AUTHORS
Yuhuang Wang, Yanli Zhao2, Jianping Zhang, MD3, Min Xiong4, Xingyu Cao, MD5, Deyan Liu6, Ruijuan Sun7, Zhijie Wei8, Jiarui Zhou9, Jing Long10, Peihua (Peggy) Lu, MD11, Yue Lu, PhD12
AFFILIATIONS
1 Hebei Yanda Ludaopei hospital, Langfang, China
2 Hebei Yanda Ludaopei Hospital, Langfang City, Hebei Province, China
3 Hebei Yanda Ludaopei Hospital, Langfang City, Hebei Province, China
4 Hebei Yanda Ludaopei Hospital, Langfang City, Hebei Province, China
5 Hebei Yanda Ludaopei Hospital, Langfang City, Hebei Province, China
6 Hebei Yanda Ludaopei Hospital, Langfang City, Hebei Province, China
7 Hebei Yanda Ludaopei Hospital, Langfang City, Hebei Province, China
8 Hebei Yanda Ludaopei Hospital, Langfang City, Hebei Province, China
9 Hebei Yanda Ludaopei Hospital, Langfang City, Hebei Province, China, Hebei Yanda Ludaopei Hospital, Langfang City, Hebei Province, China
10 Hebei Yanda Ludaopei Hospital, Langfang City, Hebei Province, China
11 Hebei Yanda Ludaopei Hospital, Langfang City, Hebei Province, China
12 Hebei Yanda Ludaopei Hospital, Langfang City, Hebei Province, China
ABSTRACT
Background
NUP214-rearranged acute leukemia (NUP214-r AL) is a rare, high-risk leukemia with substantial biological heterogeneity. Whether fusion partners determine transplant responsiveness and modify the prognostic significance of pre-transplant molecular measurable residual disease (MRD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains unknown.
Methods
We retrospectively analyzed 73 consecutive patients with NUP214-r AL undergoing first allo-HSCT between 2014 and 2024, including DEK::NUP214, SET::NUP214, and NUP214::ABL1 partners. Fusion transcript MRD was monitored by quantitative RT-PCR. Overall survival (OS), leukemia-free survival (LFS), cumulative incidence of relapse (CIR), and non-relapse mortality (NRM) were analyzed according to fusion partner, disease subtype, and pre-transplant molecular response.
Results
The cohort included 31 DEK::NUP214 (42.5%), 35 SET::NUP214 (47.9%), and 7 NUP214::ABL1 (9.6%) patients. Distinct biological characteristics were observed across fusion partners. FLT3-ITD mutations occurred exclusively in DEK::NUP214 (29.0%), whereas PHF6, WT1, and NOTCH1 mutations were enriched in SET::NUP214. Before transplantation, molecular remission rates also differed substantially, with fusion transcript negativity achieved in 83.9% of DEK::NUP214 compared with only 42.9% of SET::NUP214 patients. After a median follow-up of 25.9 months, significant survival heterogeneity was observed among fusion subtypes. Two-year OS was 80.0% for DEK::NUP214, 53.4% for SET::NUP214, and 100% for NUP214::ABL1 (P=0.021), while corresponding LFS was 77.0%, 51.4%, and 100% (P=0.017). NRM was also markedly higher in SET::NUP214 than DEK::NUP214 (31.4% vs. 9.7%, P=0.040), whereas CIR remained comparable.
Fusion partner fundamentally altered the prognostic significance of pre-transplant molecular MRD. Among DEK::NUP214 patients, persistent fusion transcript positivity before allo-HSCT did not significantly affect post-transplant outcomes, with comparable 3-year OS (76.9% vs. 91.7%), LFS (69.2% vs. 90.0%), CIR (15.4% vs. 8.3%), and NRM (23.1% vs. 0%) between molecularly positive and negative patients (all P>0.05). Despite the exclusive occurrence of FLT3-ITD in DEK::NUP214, transplant outcomes were comparable between FLT3-mutated and FLT3-wild-type patients (3-year OS, 77.9% vs. 81.9%; P=0.744), suggesting that allo-HSCT largely mitigated the adverse prognostic effect of FLT3-ITD.
In contrast, persistent SET::NUP214 positivity identified a high-risk subgroup with markedly inferior 3-year OS (23.1% vs. 74.7%, P=0.004) and LFS (23.1% vs. 70.0%, P=0.017), together with substantially higher CIR (38.5% vs. 15.0%) and NRM (46.2% vs. 15.0%). Further analyses demonstrated profound biological heterogeneity within SET::NUP214 leukemia. Patients with SET::NUP214-associated ALL achieved favorable outcomes (3-year OS/LFS, 68.1%/68.1%), whereas SET::NUP214-associated AML showed intermediate survival (66.7%/66.7%). In striking contrast, SET::NUP214-associated MPAL had an extremely poor prognosis, with only 20.0% 3-year OS, 10.0% LFS, 50.0% relapse, and 40.0% NRM.
Distinct relapse kinetics further supported the biological differences between fusion partners. Among patients with post-transplant molecular recurrence, isolated molecular relapse occurred exclusively in DEK::NUP214, and two patients remained free of hematologic relapse after preemptive therapy (chemotherapy plus DLI). In contrast, all nine SET::NUP214 patients with molecular recurrence subsequently developed overt hematologic relapse, including eight (88.9%) within one year after transplantation.
Conclusions
Fusion partner fundamentally determines transplant responsiveness and the clinical interpretation of pre-transplant molecular MRD in
NUP214-r acute leukemia. Persistent molecular disease before transplantation can be effectively overcome in
DEK::NUP214 but not in
SET::NUP214, supporting fusion partner-specific MRD-guided transplant risk assessment and post-transplant surveillance. In addition,
SET::NUP214-associated MPAL may represent a distinct ultra-high-risk transplant subgroup.
DISCLOSURES
Yuhuang Wang: No relevant conflicts of interest to declare.